ArticleFrontiers in microbiology2017
Production of Ramoplanin and Ramoplanin Analogs by Actinomycetes.
Article in Frontiers in microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 32 citations in OpenAlex.
- Antibiotic-producing microorganisms: taxonomic diversity, screening strategies, and emerging and underexploited antibacterial targets.Archives of microbiology · 2026Review
- Targeting Transcriptional Regulators Affecting Acarbose Biosynthesis inMicroorganisms · 2024Article
- Discovery of thiazostatin D/E using UPLC-HR-MS2-based metabolomics and σ-factor engineering ofFrontiers in bioengineering and biotechnology · 2024Article
- Unveiling metabolo-genomic insights of potent antitumoral and antibiotic activity inFrontiers in microbiology · 2024Article
- Natural Products Dereplication: Databases and Analytical Methods.Progress in the chemistry of organic natural products · 2024Review
- Exploring the biosynthetic gene clusters in Brevibacterium: a comparative genomic analysis of diversity and distribution.BMC genomics · 2023Article
- Article
- Article
- Structural diversity, bioactivity, and biosynthesis of phosphoglycolipid family antibiotics: Recent advances.BBA advances · 2022Article
- Emerging peptide antibiotics with therapeutic potential.Medicine in drug discovery · 2021Review
- Tackling Antibiotic Resistance with Compounds of Natural Origin: A Comprehensive Review.Biomedicines · 2020Review
- An Update on Antimicrobial Peptides (AMPs) and Their Delivery Strategies for Wound Infections.Pharmaceutics · 2020Review
- Minimal exposure of lipid II cycle intermediates triggers cell wall antibiotic resistance.Nature communications · 2019Article
- Therapeutic compounds targeting Lipid II for antibacterial purposes.Infection and drug resistance · 2019Article
- Biodiversity of Actinobacteria from the South Pacific and the Assessment of Streptomyces Chemical Diversity with Metabolic Profiling.Marine drugs · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ramoplanin is a glycolipodepsipeptide antibiotic obtained from fermentation of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.